Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan
- PMID: 30560315
- DOI: 10.1007/s12185-018-02564-z
Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan
Abstract
The authors would like to correct the errors in the publication of the original article. The correction details are given below.
Erratum for
-
Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan.Int J Hematol. 2019 Jan;109(1):70-78. doi: 10.1007/s12185-018-2499-y. Epub 2018 Jul 24. Int J Hematol. 2019. PMID: 30043332
Publication types
LinkOut - more resources
Full Text Sources